Myelodysplastic Syndromes (MDS) Clinical Trials at the Mario Lemieux Center for Blood Cancers

To learn more or speak with a trial coordinator, please call 412-864-6600.

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in subjects with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.

Principal Investigator: Jing Hou, MD, PhD
Sponsor: AbbVie

View eligibility criteria and the full trial at ClinicalTrials.gov.

Evaluate the safety and efficacy of CC-486 and durvalumab in subjects with myelodysplastic syndromes who failed to achieve an objective response post iHMA treatment.

Principal Investigator: Robert Redner, MD
Sponsor: Celgene

View eligibility criteria and the full trial at ClinicalTrials.gov.